Mereo BioPharma's Alvelestat Shows Improvement In COVID-19 Severity

The University of Alabama at Birmingham (UAB) and Mereo BioPharma Group plc MREO announced topline data from a Phase 1b/2 trial of alvelestat in hospitalized COVID-19 Respiratory Disease patients.

  • Consistent with the known safety profile of alvelestat, no safety signals were observed in lab safety monitoring, including none in liver, renal and vital sign parameters.
  • Treatment-emergent headaches were more frequent in the alvelestat arm than placebo. 
  • In the alvelestat arm, 62.5% of patients had a 2-point decrease in the WHO Disease Severity score by Day 5, compared to 28.5% patients in the placebo arm. 
  • On Day 7, the improvement in WHO Severity score increased to 87.5% in the alvelestat arm and 57% in the placebo arm.
  • A more significant reduction in C-reactive Protein was observed in alvelestat compared to placebo (p=0.143).
  • In addition, there was a reduction in D-Dimer in the alvelestat arm compared to the placebo arm, which increased over the treatment period (p=0.199). 
  • Price Action: MREO shares are trading at $1.65 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsCOVID-19 CoronavirusPhase 1 TrialPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!